Biochemicals and Reagents

The AURKA antibody is a highly effective neutralizing agent used in Life Sciences research. It belongs to a class of inhibitors that target specific proteins involved in cellular processes. This monoclonal antibody has been extensively tested and proven to be highly cytotoxic against various cancer cell lines. In addition, it has shown promising results in inhibiting the growth factor signaling pathway and blocking the activity of leukemia inhibitory factor. The AURKA antibody is derived from human serum and exhibits excellent specificity and affinity for its target protein. Its colloidal nature allows for easy handling and application in various experimental setups. Researchers can rely on this monoclonal antibody to accurately detect and quantify the presence of hormone peptides, autoantibodies, and other biomolecules of interest.

PROTAC CDK9 Degrader-1 is a combination therapy that includes two different types of drugs. One drug inhibits the activity of cyclin-dependent kinases (CDKs). The other drug inhibits the activity of autophagy enzymes. Together, these drugs inhibit the growth of cancer cells and are currently being investigated as a treatment for leukemia and lymphoma in human patients.

Erso is a medicinal compound that has been developed to target cancer cells by disrupting the cell cycle and inducing apoptosis. It works by inhibiting the activity of kinases, which are enzymes that play a key role in regulating cell growth and division. Erso has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and induce cancer cell death in both Chinese hamster ovary cells and human cancer cell lines. The protein inhibitor also shows potential for use as a diagnostic tool, as it can be detected in urine samples of patients with certain types of cancer. With its targeted approach to fighting cancer, Erso is poised to become an important tool in the fight against this devastating disease.

Meseclazone is a non-steroidal anti-inflammatory drug (NSAID) that is used to treat inflammation, pain, and stiffness caused by arthritis. Meseclazone is a prodrug that is converted in vivo to mesalazine, its active form. Mesalazine has been shown to have biological properties that are similar to acetylsalicylic acid, including ionotropic gelation. This drug also has the ability to form hydrogen bonds with acidic or basic groups, which helps it act as a cavity filler. Meseclazone also contains a carbonyl group and hydrochloric acid, which can be used for the synthesis of other drugs.

TNF-± Antagonist III is a drug that is used to inhibit the production of TNF-α. It has been shown to regulate transcriptional activity in cells and to inhibit the growth of cancer cells. TNF-± Antagonist III has been observed to decrease the M2 phenotype, which may be due to its ability to activate ATP levels in macrophages. This drug also inhibits kidney fibrosis by reducing pro-inflammatory factors, such as tumor necrosis factor-α (TNF-α) and fatty acids. The drug also has effects on abdominal surgery, as it reduces inflammation following this type of procedure. TNF-± Antagonist III is used in fat tissue and adipose tissue, where it reduces the number of pro-inflammatory factors produced by macrophages.

Temarotene is an all-trans retinoic acid (ATRA) analog that binds to the IL-2 receptor with high affinity and specificity. It has been shown to inhibit the proliferation of HL-60 cells in vitro, which may be due to its ability to induce the release of colony-stimulating factor from these cells. Temarotene also enhances the uptake of ATRA by HL-60 cells and increases the expression of receptors for ATRA in humans. In vivo studies have shown that temarotene is a potent inducer of fatty acid synthesis in Sprague-Dawley rats. This agent has a long half-life and is rapidly absorbed when administered orally, with peak plasma concentrations occurring 2 hours after administration. The pharmacokinetic properties of this drug are similar to those of other synthetic retinoids, such as all-trans-retinoic acid.

2-Methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-(trifluoromethyl)quinazolin-4-one is a potent and selective inhibitor of the type I phosphodiesterase (PDE1). It has been shown to inhibit PDE1 in human platelets and erythrocytes. It also inhibits the activation of protein kinase C by thrombin. This agent binds to a region on PDE1 that does not overlap with the binding site for most PDE inhibitors, suggesting that it may be useful as an alternative treatment for conditions such as asthma and inflammation.

Inhibitor of CK1 kinase

MSG 606 is a mitochondrial fission inhibitor that has been shown to reduce microglial activation, neuroinflammation and the release of neutrophils from the bone marrow. This drug also has neuroprotective properties and can be used for treatment of neurodegenerative disorders. MSG 606 is an investigational drug, not approved for human use.

Itraconazole-d5 is a fluorescent derivative of itraconazole that is used for the detection of eosinophil cationic protein in the diagnosis of asthma. It binds to wild-type strains and inhibits fungal enzyme activities, such as concentration–time curves and minimal toxicity. The hydrogen bonding interactions between itraconazole-d5 and its target molecule are stronger than those between itraconazole and its target molecule. Itraconazole-d5 has been shown to inhibit the production of cationic proteins by inhibiting the activity of enzymes, such as polymerase chain reaction (PCR) and reverse transcriptase (RT), which are required for DNA synthesis.

ITMN 4077 is an ion channel activator that belongs to the group of peptides. It is a synthetic peptide with a high purity, and has been shown to be an inhibitor of sodium channels in neuronal cells. ITMN 4077 may be used as a research tool to study protein interactions, such as those between ion channels and their ligands. This compound may also be used for pharmacological purposes or for the treatment of diseases caused by abnormal ion channel activity, such as epilepsy or chronic pain.

Rilpivirine-d6 is a deuterated, stable isotope of rilpivirine. It is used to investigate the metabolism of drugs in plasma samples and tissues for bioequivalence studies. Rilpivirine-d6 is used as an internal standard in quantitative analysis by mass spectrometry. The stability of this molecule enables it to be used in prolonged studies without significant degradation. Rilpivirine-d6 has been shown to reduce viral load and increase CD4+ T cell counts in HIV patients who are on antiretroviral therapy. Rilpivirine-d6 binds to the reverse transcriptase enzyme and prevents the formation of DNA from RNA, thus inhibiting viral replication.

Collismycin A is a biocompatible polymer with a strong antimicrobial activity. It has been shown to act as an inhibitor of the picolinic acid-dependent, nitrogen atom-containing enzyme, alpha-ketoglutarate aminotransferase. This inhibition leads to a decrease in the production of inflammatory mediators and autoantibodies. Collismycin A has also been shown to have immunomodulatory properties and may be useful for treating autoimmune diseases.

N-Methyl moxifloxacin hydrochloride is an analog of the fluoroquinolone antibiotic, Moxifloxacin. It functions as a potent inhibitor of human kinases and has shown promising anticancer activity in preclinical studies. N-Methyl moxifloxacin hydrochloride has been shown to inhibit the growth of tumor cells and induce apoptosis in cancer cells. This drug also exhibits inhibitory effects against linezolid-resistant strains of staphylococcus aureus and has synergistic effects when combined with artesunate, an antimalarial drug. N-Methyl moxifloxacin hydrochloride is excreted primarily through urine and is well-tolerated in Chinese patients.

SB 204741 is a drug that blocks the action of serotonin receptors. It is used in the treatment of autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus. SB 204741 has been shown to reduce levels of cytosolic calcium, which may be due to its inhibition of phospholipase C. This drug also inhibits the polymerase chain reaction and slows cardiac muscle cell growth. In addition, it inhibits the release of growth factor-β1 from platelets and 5-hydroxytryptamine (5-HT) from synaptosomes in rat brain cells. SB 204741 also has a synergistic effect with detrusor muscle relaxants and potentiates the effects of selective 5-HT2C receptor antagonists on 5-HT2B receptors.

Bisphenol A-d6 diglycidyl ether is a deuterated form of an epoxy resin prepolymer, which is a vital compound in polymer chemistry and materials science. It is synthesized through the glycidylation of deuterated bisphenol A, introducing stable isotopic labeling with six deuterium atoms. This isotopic form retains the structural integrity of Bisphenol A diglycidyl ether but enhances its utility in specific scientific applications.

Please enquire for more information about 2-Bromo-5-fluorobenzyl acetate including the price, delivery time and more detailed product information at the technical inquiry form on this page

S-Acebutolol-d7 is a medicinal compound that has shown promising results in the treatment of cancer. It is an analog of Acebutolol, a beta-blocker that is commonly used to treat hypertension and arrhythmias. S-Acebutolol-d7 has been found to be an effective inhibitor of protein kinases, which are enzymes that play a key role in the regulation of cell growth and division. This compound induces apoptosis (programmed cell death) in cancer cells and has been shown to inhibit tumor growth in human cancer cell lines. Additionally, S-Acebutolol-d7 has demonstrated anticancer activity by blocking the cell cycle progression and suppressing the activity of inhibitors such as Chinese hamster ovary cells. This compound can be detected in urine samples and may have potential as a novel therapeutic agent for cancer treatment.

Please enquire for more information about Cis-asenapine including the price, delivery time and more detailed product information at the technical inquiry form on this page

Flupyrimin-d4 is a potent protein kinase inhibitor that has shown promising results in anticancer research. It is an analog of Flupyrimin, which has been used as a medicinal compound for treating various diseases. Flupyrimin-d4 has been found to induce apoptosis in cancer cells and inhibit the activity of kinases, which are enzymes that play a crucial role in cell signaling pathways. Studies have shown that Flupyrimin-d4 is effective against various types of cancer, including human bladder and lung cancer. This drug can be detected in urine samples, making it a useful tool for monitoring treatment efficacy. The Chinese have also used Flupyrimin-d4 as a traditional medicine for treating tumors. With its potential as an anticancer agent, Flupyrimin-d4 holds promise for the development of novel cancer therapies.

Briciclib disodium is a prodrug that is administered in the form of a tablet. It is used as an antineoplastic agent to treat cancer. Briciclib disodium is an analog of benzyl bromide, which is a diagnostic agent and has been used in the past to study translation and profiles. This drug can be detected in body fluids such as urine, serum, or plasma. Briciclib disodium has been shown to have potential anti-neoplastic properties and can be used for the treatment of cavity or cancer.

X5050 is a Chinese medicinal product that has been found to have potent anticancer properties. It is an inhibitor of protein kinases, which are enzymes that play a crucial role in the growth and survival of cancer cells. X5050 has been shown to induce apoptosis, or programmed cell death, in cancer cells, leading to the suppression of tumor growth. This product has also been found to be effective against various types of cancer, including breast cancer and lung cancer. X5050 is an analog of a natural compound found in human urine and has been extensively studied for its medicinal properties. Its unique mechanism of action makes it a promising candidate for the development of new anticancer drugs.

ML-213 is a cationic, non-selective drug that is membrane hyperpolarizing. It has been shown to increase the intracellular Ca2+ concentration in cells and to inhibit the growth of human liver, bladder, and mesenteric cells. ML-213 also exhibits selective activities against human lung cancer cells in vitro. It binds to DNA polymerase, preventing transcription and replication. This drug also inhibits the activity of protein kinases by binding to their ATP binding site. The conformational properties of ML-213 have been studied using NMR spectroscopy and found to be affected by alcohol exposure.

Biphalin trifluoroacetate salt is a research tool for the study of ion channels and ligand-receptor interactions. It is used in pharmacology to study the function of ion channels and ligand-receptor interactions. Biphalin trifluoroacetate salt also has a high purity, which makes it suitable for use in life science research. The biphalin molecule can be used as an activator or an antibody to activate certain receptors.

VU 0365114 is a novel compound that is synthesized to act as an allosteric modulator of the acetylcholine receptor. It has been shown to have antagonistic properties at the receptor subtype. VU 0365114 has been found to be active in knockout mice, and it was able to produce effects in the ventral tegmental area and substantia nigra. The drug was also able to increase phosphatidyl fumarate levels, which may be due to its ability to inhibit fumarate reductase activity.